2018
Challenges with biomarkers in cancer drug discovery and development
Search citation statements
Paper Sections
Select...
38
5
3
0
Citation Types
0
23
0
0
Year Published
2017
2026
Publication Types
Select...
28
9
4
4
Relationship
1
44
Authors
Journals
Cited by 38 publications
(23 citation statements)
References 29 publications
0
23
0
0
“…PI3K/mTOR inhibitors are just one example of drugs for which a clear predictive marker is lacking, and patient with or without PI3K alterations have been shown to respond to PI3K inhibitors 39 . In fact, the absence of specific, unequivocal biomarkers predictive of response is a common limitation and challenge associated with the clinical implementation of many kinase inhibitors 40,41 . Our assay could bypass the lack of predictors of response and identify responsive tumors from a functional standpoint.…”
Section: Discussionmentioning
confidence: 99%
“…PI3K/mTOR inhibitors are just one example of drugs for which a clear predictive marker is lacking, and patient with or without PI3K alterations have been shown to respond to PI3K inhibitors 39 . In fact, the absence of specific, unequivocal biomarkers predictive of response is a common limitation and challenge associated with the clinical implementation of many kinase inhibitors 40,41 . Our assay could bypass the lack of predictors of response and identify responsive tumors from a functional standpoint.…”
Section: Discussionmentioning
confidence: 99%
“…It is still unclear how SFRP4 gene expression is related to the Wnt-signaling in tissue. A cancer biomarker can either be a driver or a passenger of cancer development 44 . It is possible that elevated SFRP4 mRNA is merely a consequence (i.e.…”
Section: Discussionmentioning
confidence: 99%
“…Recently, many technologies, including gene expression profiling, transcriptome, proteomics, and metabolomics platforms have been explored for the discovery of novel biomarkers that can reflect tumor progression, infectious, and autoimmune diseases ( 23 , 24 ). Due to the heterogeneity in the tumor environment, and new mutations that cancer cells acquire during the progression from localized disease to advanced disease, identifying tumor markers is a challenge for biomedical and biotechnological research.…”
Section: Discussionmentioning
confidence: 99%
